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AdultABSTRACT
Neurocysticercosis is thought to be the most common helminthic infection of the central
nervous system and its epidemiology is changing due to increasing travel and migration.
Evidence to guide management of the intraventricular form is limited. We aimed to re-
view the clinical presentation, diagnosis and treatment of intraventricular neuro-
cysticercosis with reference to two recent cases seen at our institution. The
intraventricular variant of neurocysticercosis is less common than parenchymal disease
and usually presents with acutely raised intracranial pressure and untreated it progresses
rapidly with high mortality. The diagnosis is based on imaging and serological tests but
more invasive testing including histopathological examination of surgically acquired
tissue specimens is sometimes required. Treatment is mainly surgical, using a neuro-
endoscopic approach if possible. Patients should also receive antihelmintic treatment with
concomitant corticosteroids to reduce the incidence of shunt failure if a ventricular shunt
is inserted and to treat viable lesions elsewhere.1. Introduction
Neurocysticercosis is the most important helminthic central
nervous system (CNS) infection worldwide and increasing travel
and migration has led to a growing number of patients being
diagnosed in non-endemic countries [1]. The majority of the
published literature relates to the parenchymal form of the
disease, and there is a paucity of epidemiological studies and
high quality evidence to guide the management of the
intraventricular variant.
Cysticercosis occurs when eggs from Taenia solium (T.
solium), the pork tapeworm, are ingested by humans who
become dead-end intermediate hosts. Oncospheres migrate to
various tissues, most commonly the CNS, eyes, muscles and
subcutaneous tissues, and once fully developed as viable cysts,
go through three consecutive distinct stages in the process of
degeneration: colloidal, granular and calciﬁed forms [2]. In
intraventricular neurocysticercosis, the larvae reach the
cerebral ventricles via the choroid plexus and cause symptoms
either from obstructing CSF ﬂow, ependymitis or both [3,4].No recent population based prospective data is available on
the frequency and pattern of intraventricular involvement in
neurocysticercosis. Several studies, including the largest series
available, were done prior to the introduction of MRI and CT
scanning, and most were from non-endemic countries. The
majority of recent publications are from neurosurgical journals,
so signiﬁcant referral bias can be expected since parenchymal
neurocysticercosis is mainly managed medically and is less
likely to involve surgical consultation. Intraventricular disease
has been reported to occur in between 7.3% and 61.3% of cases
of neurocysticercosis [3,5,6]. Cysts are most often found in the
fourth ventricle (range 43%–70%) followed by the lateral
(11%–43%) and third (1%–29%) ventricles with a minority in
the Sylvean aqueduct (7%–9%) [3,5,7–9]. Compared to
parenchymal neurocysticercosis, patients with intraventricular
disease have a worse overall outcome and most deaths occur
in this subgroup [10].
We report two cases of intraventricular neurocysticercosis
that illustrate the natural history, diagnostic and management
issues.
2. Case report 1
A 30 year old Indonesian female presented in 2004 with
acute headache, fever and confusion. On examination she had
neck stiffness with no focal motor or sensory deﬁcits. She had aCC BY-NC-ND license (http://
Figure 1. Findings on imaging and histopathology in two cases of neurocysticercosis.
A: CT scan of brain (Case 1) demonstrating dilated lateral and third ventricles as well as effaced cerebral sulci; B: Histopathological examination, hae-
matoxylin and eosin stain at magniﬁcation ×100 (Case 1) showing three distinct layers consistent with a T. solium cyst: a cuticular layer with hair-like
microtrichia, a middle cellular layer and an inner reticular layer with focal calciﬁcation; C: MRI brain (Case 2) identifying a bilobed cyst in the fora-
men of Monro and severe obstructive hydrocephalus; D: CT scan of brain (Case 2) after relief of hydrocephalus showing multiple tiny calciﬁcations
throughout both hemispheres.
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were neutrophils, and blood tests including HIV serology were
otherwise unremarkable. A CT scan showed moderate dilatation
of lateral and third ventricles, a normal sized fourth ventricle and
effacement of all cerebral sulci (Figure 1a).
Empiric treatment for bacterial meningitis was started and
emergency external ventricular drains were inserted into both
lateral ventricles. CSF collected at the time of drain insertion
contained 6 × 106 white cells per litre of which 5 × 106 were
polymorphonuclear cells and no organisms were identiﬁed on
Gram stain or standard bacterial culture. The CSF levels of
glucose and protein were 4.4 mmol/L and 0.09 g/L respectively.
The patient's symptoms improved after drain insertion and a
subsequent MRI scan showed mild residual dilatation of the
lateral ventricles but the third and fourth ventricles were normal
in size and CSF ﬂow studies were normal. A post-operative
lumbar puncture showed a mild pleocytosis of 33 × 106 white
cells per litre, with 78% lymphocytes. The glucose concentration
was normal at 3.6 mmol/L and protein was normalising at
0.44 g/L. Culture for bacteria, fungi and mycobacteria were all
negative.
On endoscopic third ventriculostomy a large cyst with a
white membranous wall was found protruding through the fo-
ramen of Monro. Histopathological examination of the cyst was
consistent with cysticercosis (Figure 1b). Serum testing for
cysticercosis IgG with an enzyme-linked immunosorbent assay
(ELISA) was negative (Diagnostic Automation Inc., California,
USA).
3. Case report 2
A 50 year old female from Punjab, India was admitted in
2013 with two days of headache, nausea, irritability and
confusion. She was afebrile without focal neurological deﬁcitsand blood tests including full blood count, liver and renal
functions were normal.
The patient had been living in Australia for 30 years with
frequent trips to India to visit family. Twenty years previously
she had been diagnosed with parenchymal cysticercosis and had
a viable cyst in the right biceps muscle which was removed. She
had a brief period of dysphasia and left arm weakness at the time
of diagnosis, but these symptoms resolved.
At the time of the recent presentation a MRI scan revealed a
16 mm × 18 mm bilobed cystic lesion in the foramen of Monro,
with minimal surrounding enhancement and severe obstructive
hydrocephalus. No scolex was seen (Figure 1c). The cyst was
removed endoscopically, an external ventricular drain was
inserted and her symptoms resolved. Cerebrospinal ﬂuid
sampled at the time of surgery contained no white cells. Histo-
pathological examination showed three distinct layers consistent
with cysticercosis. No serological tests were performed on serum
or cerebrospinal ﬂuid as a conclusive histopathological diag-
nosis was made. A post-operative CT scan demonstrated reso-
lution of the hydrocephalus and multiple tiny calciﬁcations
scattered throughout cerebral and cerebellar hemispheres bilat-
erally consistent with calciﬁed cysts (Figure 1d).
4. Discussion
Management of intraventricular neurocysticercosis is distinct
from the parenchymal form for which most evidence has been
published [11,12]. Guidelines have not been validated in this
subgroup of patients and as a consequence, management is
mostly based on smaller case series and expert opinion.
As exempliﬁed by our cases, intraventricular neuro-
cysticercosis commonly presents with acute obstructive hydro-
cephalus secondary to either cyst entrapment in narrow foramina
or ependymitis [3,4]. Headache is reported in nearly all patients
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decreased visual acuity, altered mental status and cranial nerve
palsies [3,5,7–9].
The diagnosis of intraventricular neurocysticercosis is most
often made radiologically and MRI is considered the most
useful modality although no direct comparison has been made
with other techniques. Increased T1 and T2 signal of the cyst
wall is usually seen, although cysts are sometimes missed as
seen in Case 1 [3,7]. The visualisation of a scolex is diagnostic
[12]. Enhancement with gadolinium and increased intensity of
cyst content on a T1-weighted sequence indicates cyst invo-
lution in either the colloidal or granular stage which is often
associated with ependymitis [3]. A disadvantage of MRI
scanning is that its sensitivity for calciﬁed lesions is poor
compared to CT as seen in Case 2 where these were only
apparent on a CT scan after removal of the intraventricular
cyst. In the absence of a visualised scolex, intraventricular
cysticercosis can be mistaken for a benign colloid cyst as was
the case in Case 2. If a MRI scan does not reveal a cyst and
there is suspicion of neurocysticercosis, CT ventriculography
or neuroendoscopic exploration may be warranted. This was
illustrated in Case 1, where the cyst only became apparent
during endoscopy.
The inﬂammatory process in neurocysticercosis varies
markedly with parasite location [13]. The interpretation of
biochemical and serological tests on blood and CSF in
intraventricular disease is therefore problematic since most
evidence for their use come from studies in patients with
parenchymal lesions.
The current antibody test of choice is an immunoblot assay
using T. solium antigens on serum or CSF samples [14]. The
performance of this test in patients with intraventricular
disease has not been adequately studied, although the
sensitivity is likely around 80% based on the analysis of small
subgroups of patients in the original studies [15]. It is unclear
if the test performs differently on serum and CSF samples and
a major drawback of antibody tests is the inability to
distinguish between active or past infection in patients who
typically come from high-prevalence regions [14].
Direct detection of T. solium antigen has the advantage of
being associated with active infection (viable, colloid and
granular stages) and disease severity, and the best studied
method is an ELISA using a monoclonal antibody against the
Taenia saginata (beef tapeworm) HP10 antigen [14]. Studies on
both serum and CSF have shown a high speciﬁcity for viable
cysts although some have reported a lower sensitivity (21.4%–
94.1%) compared to antibody assays [16,17]. In addition,
antigenaemia predicts the presence of viable cysts in patients
who only have calciﬁed lesions on CT making it useful in
settings where MRI is not available [18]. In intraventricular
neurocysticercosis the antigen levels are often higher,
speciﬁcity is close to 100% and serial monitoring with the
HP10 assay is a useful way of conﬁrming the disappearance
of viable cysts with treatment [17]. Applying the antigen
detection assay to CSF is unlikely to result in better sensitivity
and speciﬁcity than when used on serum [17].
Detection of T. solium speciﬁc DNA in CSF by polymerase
chain reaction has been studied in a small number of patients
with intraventricular neurocysticercosis where it had variable
sensitivity (71%–97%) using different primers [14,16]. Larger
studies are still needed to conﬁrm its use in intraventricular
disease, and its use is limited by cost in most endemic areas.A CSF pleocytosis, which is absent in up to one third of cases,
is usually below 500 × 106 cells per litre and consists mainly of
lymphocytes and infrequently eosinophils [5]. These changes
have been found to be more marked when measured by lumbar
puncture compared to sampling directly from ventricles.
Histopathological demonstration of T. solium cysts is an
absolute diagnostic criterion in parenchymal neurocysticercosis
and although these criteria are not validated for intraventricular
disease, this was how the diagnosis was conﬁrmed in both our
cases [12]. If only the membranous structures are found, they
include an outer eosinophilic layer, a middle cellular layer
with between one and three rows of lymphocyte-like cells and
ﬁnally an inner reticular layer. Because the scolex and mem-
brane lose their distinct features during the degeneration process,
a histopathological diagnosis is limited to the viable stage.
The treatment of neurocysticercosis includes antihelmintic
drugs and surgical resection of lesions as well as symptomatic
treatment with analgesia, anti-inﬂammatory drugs and anti-
epileptics.
Surgical intervention is usually warranted acutely in intra-
ventricular neurocysticercosis to relieve pressure and remove
cysts [4]. Traditionally, treatment comprised of emergency shunt
placement and cyst removal by open craniotomy allowing for
antihelmintic treatment, which generally has poor efﬁcacy.
Neuroendoscopic cyst resection with ventriculostomy with or
without placement of an external ventricular drain or
permanent shunt has now become the surgical treatment of
choice, resulting in less complications and higher cure rates
and this may be curative without anthelmintic [5,6,8,9].
Ventriculostomy at the time of procedure is often enough to
relieve hydrocephalus without external drainage which carries
a risk of bacterial infection, although it is still needed in
patients with extensive disease and ependymitis. When a shunt
is placed there is a high risk of shunt failure by blockage and
administration of antihelmintic therapy reduces this.
No trials or guidelines are available on the antihelmintic
treatment of the intraventricular form of neurocysticercosis and
it has not been determined if its use improves outcome when
added to surgery. Although medical therapy alone has been re-
ported to lead to resolution of mild cases without signiﬁcant
hydrocephalus, repeat courses are often necessary. Most clini-
cians follow the guidelines for parenchymal neurocysticercosis
from the American Academy of Neurology which recommends
albendazole (15 mg/kg/d for 8 d) and either dexamethasone or
prednisolone [11]. Praziquantel 50 mg/kg/d for 15 d is an
alternative. Although prolonged treatment with albendazole
has not been shown to improve efﬁcacy, increasing the dose
to 30 mg/kg/d was safe and more effective in a small
randomised trial in patients with extraparenchymal disease but
these results need conﬁrmation in larger studies [19].
Treatment with anthelmintic may lead to a paradoxical
worsening of symptoms or unmask previously undiagnosed
neurocysticercosis if treatment is given for another helminthic
infection. Treatment should therefore be given under observa-
tion in hospital with concomitant corticosteroid administration
and in this setting it is thought to be safe [20]. Moderate doses of
either dexamethasone (0.1 mg/kg/d) or prednisolone (1 mg/kg/d)
are usually given for the duration of antihelmintic treatment but
the dose and duration may have to be increased in cases with
marked symptoms or a large number of viable cysts.
Corticosteroids have been shown to reduce the plasma level of
praziquantel supporting the preferential use of albendazole.
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Intraventricular disease occurs in a signiﬁcant minority of
patients with neurocysticercosis, which is no longer an infection
that is restricted geographically to resource-poor regions. The
presentation is with features of raised intracranial pressure and
the untreated the mortality is high. The diagnosis is based on
imaging with MRI, but serological tests, PCR, histopathology
and direct surgical visualisation are important supplementary
diagnostic tools. Treatment is mainly surgical, preferably using a
neuroendoscopic technique, but patients should receive anti-
helmintic treatment with concomitant corticosteroids to reduce
incidence of shunt failure if a ventricular shunt is inserted and to
treat undiagnosed viable lesions elsewhere.
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